World journal of experimental medicine最新文献

{"title":"Management of male obesity-related secondary hypogonadism: A clinical update.","authors":"Mohan T Shenoy, Sunetra Mondal, Cornelius James Fernandez, Joseph M Pappachan","doi":"10.5493/wjem.v14.i2.93689","DOIUrl":"10.5493/wjem.v14.i2.93689","url":null,"abstract":"<p><p>The global obesity pandemic has resulted in a rise in the prevalence of male obesity-related secondary hypogonadism (MOSH) with emerging evidence on the role of testosterone therapy. We aim to provide an updated and practical approach towards its management. We did a comprehensive literature search across MEDLINE (<i>via</i> PubMed), Scopus, and Google Scholar databases using the keywords \"MOSH\" OR \"Obesity-related hypogonadism\" OR \"Testosterone replacement therapy\" OR \"Selective estrogen receptor modulator\" OR \"SERM\" OR \"Guidelines on male hypogonadism\" as well as a manual search of references within the articles. A narrative review based on available evidence, recommendations and their practical implications was done. Although weight loss is the ideal therapeutic strategy for patients with MOSH, achievement of significant weight reduction is usually difficult with lifestyle changes alone in real-world practice. Therefore, androgen administration is often necessary in the management of hypogonadism in patients with MOSH which also improves many other comorbidities related to obesity. However, there is conflicting evidence for the appropriate use of testosterone replacement therapy (TRT), and it can also be associated with complications. This evidence-based review updates the available evidence including the very recently published results of the TRAVERSE trial and provides comprehensive clinical practice pearls for the management of patients with MOSH. Before starting testosterone replacement in functional hypogonadism of obesity, it would be desirable to initiate lifestyle modification to ensure weight reduction. TRT should be coupled with the management of other comorbidities related to obesity in MOSH patients. Balancing the risks and benefits of TRT should be considered in every patient before and during long-term management.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"93689"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Realm of hepatitis E: Challenges and opportunities.","authors":"Jia-Rui Li, Ze Xiang, Shu-Hui Li, Chen-Xi Li, Hong Yan, Jian Wu","doi":"10.5493/wjem.v14.i2.90481","DOIUrl":"10.5493/wjem.v14.i2.90481","url":null,"abstract":"<p><p>Hepatitis E virus (HEV), responsible for widespread viral hepatitis, infects approximately 2.3 billion individuals globally, with a significant mortality burden in Asia. The virus, primarily transmitted through contaminated water and undercooked meat, is often underdiagnosed, particularly in immunocompromised patients. Current HEV treatments, while effective, are limited by adverse effects, necessitating research into safer alternatives. Moreover, HEV's extrahepatic manifestations, impacting the nervous and renal systems, remain poorly understood. This study underscores the imperative for enhanced HEV research, improved diagnostic methods, and more effective treatments, coupled with increased public health awareness and preventive strategies.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"90481"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose cotransporter-2 inhibitors protect tissues <i>via</i> cellular and mitochondrial pathways: Experimental and clinical evidence.","authors":"Raúl Lelio Sanz, Sebastián García Menéndez, Felipe Inserra, Leon Ferder, Walter Manucha","doi":"10.5493/wjem.v14.i2.91519","DOIUrl":"10.5493/wjem.v14.i2.91519","url":null,"abstract":"<p><p>Mitochondrial dysfunction is a key driver of cardiovascular disease (CVD) in metabolic syndrome and diabetes. This dysfunction promotes the production of reactive oxygen species (ROS), which cause oxidative stress and inflammation. Angiotensin II, the main mediator of the renin-angiotensin-aldosterone system, also contributes to CVD by promoting ROS production. Reduced activity of sirtuins (SIRTs), a family of proteins that regulate cellular metabolism, also worsens oxidative stress. Reduction of energy production by mitochondria is a common feature of all metabolic disorders. High SIRT levels and 5' adenosine monophosphate-activated protein kinase signaling stimulate hypoxia-inducible factor 1 beta, which promotes ketosis. Ketosis, in turn, increases autophagy and mitophagy, processes that clear cells of debris and protect against damage. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a class of drugs used to treat type 2 diabetes, have a beneficial effect on these mechanisms. Randomized clinical trials have shown that SGLT2i improves cardiac function and reduces the rate of cardiovascular and renal events. SGLT2i also increase mitochondrial efficiency, reduce oxidative stress and inflammation, and strengthen tissues. These findings suggest that SGLT2i hold great potential for the treatment of CVD. Furthermore, they are proposed as anti-aging drugs; however, rigorous research is needed to validate these preliminary findings.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"91519"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of the time of refractive stability after uneventful phacoemulsification in Indian eyes.","authors":"Ashok Kumar Nanda, Bijnya Birajita Panda, Asish Swain, Logesh Balakrishnan","doi":"10.5493/wjem.v14.i2.95016","DOIUrl":"10.5493/wjem.v14.i2.95016","url":null,"abstract":"<p><strong>Background: </strong>Knowledge about refractive stabilization and the accuracy of postoperative refractive error measurements are crucial for improved patient outcomes after phacoemulsification. Existing guidelines typically recommend waiting 4-6 wk before prescribing corrective lenses. Our research focused on identifying factors that influence refractive errors in the early stages of post-cataract surgery, thus contributing to the existing literature on this topic.</p><p><strong>Aim: </strong>To investigate the time required for refraction stability after uneventful phacoemulsification surgery.</p><p><strong>Methods: </strong>We compared the variation and statistical significance of the difference in spherical, cylindrical components, and the spherical equivalent between the 1- and 6-wk follow-up period in a group of 257 eyes that underwent uneventful phacoemulsification with foldable intraocular lens implantation, all performed by a single experienced surgeon. The Wilcoxon-Signed Rank Test was utilized to assess the magnitude of the change and determine its statistical significance. The refractive stability was defined as the point at which the change in spherical equivalent was within ± 0.5 dioptres for two consecutive visits.</p><p><strong>Results: </strong>The average age of the patients was 64.9 ± 8.9 yr. The differences observed in both the visits in spherical power (0.1 ± 0.2), cylinder power (0.3 ± 0.4), and spherical equivalent (0.2 ± 0.2) were minimal and not statistically significant. The majority of eyes (93.4%) achieved refractive stability within 6 wk after the surgery. The cylindrical power differed between age groups at the 6^th wk post-operative and the difference was statistically significant (<i>P</i> value 0.013). There were no significant differences in refractive stability when considering sex and axial length.</p><p><strong>Conclusion: </strong>Phacoemulsification with foldable intraocular lens implantation results in no significant changes in refraction for the majority of cases during the 6-wk follow-up period. Therefore, a spectacle prescription can be given at the completion of 1 wk.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"95016"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eribulin in breast cancer: Current insights and therapeutic perspectives.","authors":"Oliver Oey, Wynne Wijaya, Andrew Redfern","doi":"10.5493/wjem.v14.i2.92558","DOIUrl":"10.5493/wjem.v14.i2.92558","url":null,"abstract":"<p><p>Eribulin is a non-taxane synthetic analogue approved in many countries as third-line treatment for the treatment of patients with metastatic breast cancer. In addition to its mitotic property, eribulin has non-mitotic properties including but not limited to, its ability to induce phenotypic reversal of epithelial to mesenchymal transition, vascular remodelling, reduction in immunosuppressive tumour microenvironment. Since approval, there has been a surge in studies investigating the application of eribulin as an earlier-line treatment and also in combination with other agents such as immunotherapy and targeted therapy across all breast cancer sub-types, including hormone receptor positive, HER2 positive and triple negative breast cancer, many demonstrating promising activity. This review will focus on the application of eribulin in the treatment of metastatic breast cancer across all subtypes including its role as an earlier-line agent, its toxicity profile, and potential future directions.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"92558"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experimental models of high-risk bowel anastomosis in rats: A systematic review.","authors":"Georgios Ntampakis, Manousos-Georgios Pramateftakis, Elissavet Anestiadou, Stefanos Bitsianis, Orestis Ioannidis, Chryssa Bekiari, George Koliakos, Maria Karakota, Anastasia Tsakona, Angeliki Cheva, Stamatios Angelopoulos","doi":"10.5493/wjem.v14.i2.94135","DOIUrl":"10.5493/wjem.v14.i2.94135","url":null,"abstract":"<p><strong>Background: </strong>Anastomotic leaks remain one of the most dreaded complications in gastrointestinal surgery causing significant morbidity, that negatively affect the patients' quality of life. Experimental studies play an important role in understanding the pathophysiological background of anastomotic healing and there are still many fields that require further investigation. Knowledge drawn from these studies can lead to interventions or techniques that can reduce the risk of anastomotic leak in patients with high-risk features. Despite the advances in experimental protocols and techniques, designing a high-quality study is still challenging for the investigators as there is a plethora of different models used.</p><p><strong>Aim: </strong>To review current state of the art for experimental protocols in high-risk anastomosis in rats.</p><p><strong>Methods: </strong>This systematic review was performed according to The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. To identify eligible studies, a comprehensive literature search was performed in the electronic databases PubMed (MEDLINE) and Scopus, covering the period from conception until 18 October 2023.</p><p><strong>Results: </strong>From our search strategy 102 studies were included and were categorized based on the mechanism used to create a high-risk anastomosis. Methods of assessing anastomotic healing were extracted and were individually appraised.</p><p><strong>Conclusion: </strong>Anastomotic healing studies have evolved over the last decades, but the findings are yet to be translated into human studies. There is a need for high-quality, well-designed studies that will help to the better understanding of the pathophysiology of anastomotic healing and the effects of various interventions.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"94135"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression levels of K_ATP channel subunits and morphological changes in the mouse liver after exposure to radiation.","authors":"Ming Zhou, Tao-Sheng Li, Hiroshi Abe, Hideo Akashi, Ryoji Suzuki, Yoshio Bando","doi":"10.5493/wjem.v14.i2.90374","DOIUrl":"10.5493/wjem.v14.i2.90374","url":null,"abstract":"<p><strong>Background: </strong>ATP sensitive K⁺ (K_ATP) channels are ubiquitously distributed in various of cells and tissues, including the liver. They play a role in the pathogenesis of myocardial and liver ischemia.</p><p><strong>Aim: </strong>To evaluate the radiation-induced changes in the expression of K_ATP channel subunits in the mouse liver to understand the potential role of K_ATP channels in radiation injury.</p><p><strong>Methods: </strong>Adult C57BL/6 mice were randomly exposed to γ-rays at 0 Gy (control, <i>n</i> = 2), 0.2 Gy (<i>n</i> = 6), 1 Gy (<i>n</i> = 6), or 5 Gy (<i>n</i> = 6). The livers were removed 3 and 24 h after radiation exposure. Hematoxylin and eosin staining was used for morphological observation; immunohistochemical staining was applied to determine the expression of K_ATP channel subunits in the liver tissue.</p><p><strong>Results: </strong>Compared with the control group, the livers exposed to 0.2 Gy γ-ray showed an initial increase in the expression of Kir6.1 at 3 h, followed by recovery at 24 h after exposure. Exposure to a high dose of 5.0 Gy resulted in decreased expression of Kir6.1 and increased expression of SUR2B at 24 h. However, the expression of Kir6.2, SUR1, or SUR2A had no remarkable changes at 3 and 24 h after exposure to any of these doses.</p><p><strong>Conclusion: </strong>The expression levels of Kir6.1 and SUR2B in mouse liver changed differently in response to different radiation doses, suggesting a potential role for them in radiation-induced liver injury.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"90374"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential and application of abortive transcripts as a novel molecular marker of cancers.","authors":"Tian-Miao Zhang, Xiao-Nian Zhu, Shao-Wei Qin, Xue-Feng Guo, Xue-Kun Xing, Li-Feng Zhao, Sheng-Kui Tan","doi":"10.5493/wjem.v14.i2.92343","DOIUrl":"10.5493/wjem.v14.i2.92343","url":null,"abstract":"<p><p>Abortive transcript (AT) is a 2-19 nt long non-coding RNA that is produced in the abortive initiation stage. Abortive initiation was found to be closely related to RNA polymerase through <i>in vitro</i> experiments. Therefore, the distribution of AT length and the scale of abortive initiation are correlated to the promoter, discriminator, and transcription initiation sequence, and can be affected by transcription elongation factors. AT plays an important role in the occurrence and development of various diseases. Here we summarize the discovery of AT, the factors responsible for AT formation, the detection methods and biological functions of AT, to provide new clues for finding potential targets in the early diagnosis and treatment of cancers.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"92343"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between acute peripancreatic fluid collections and early readmission in acute pancreatitis: A propensity-matched analysis.","authors":"Hassam Ali, Faisal Inayat, Waqas Rasheed, Arslan Afzal, Ahtshamullah Chaudhry, Pratik Patel, Attiq Ur Rehman, Muhammad Sajeel Anwar, Gul Nawaz, Muhammad Sohaib Afzal, Amir H Sohail, Subanandhini Subramanium, Dushyant Singh Dahiya, Deepa Budh, Babu P Mohan, Douglas G Adler","doi":"10.5493/wjem.v14.i2.92052","DOIUrl":"10.5493/wjem.v14.i2.92052","url":null,"abstract":"<p><strong>Background: </strong>Patients with acute pancreatitis (AP) frequently experience hospital readmissions, posing a significant burden to healthcare systems. Acute peripancreatic fluid collection (APFC) may negatively impact the clinical course of AP. It could worsen symptoms and potentially lead to additional complications. However, clinical evidence regarding the specific association between APFC and early readmission in AP remains scarce. Understanding the link between APFC and readmission may help improve clinical care for AP patients and reduce healthcare costs.</p><p><strong>Aim: </strong>To evaluate the association between APFC and 30-day readmission in patients with AP.</p><p><strong>Methods: </strong>This retrospective cohort study is based on the Nationwide Readmission Database for 2016-2019. Patients with a primary diagnosis of AP were identified. Participants were categorized into those with and without APFC. A 1:1 propensity score matching for age, gender, and Elixhauser comorbidities was performed. The primary outcome was early readmission rates. Secondary outcomes included the incidence of inpatient complications and healthcare utilization. Unadjusted analyses used Mann-Whitney <i>U</i> and <i>χ</i> ² tests, while Cox regression models assessed 30-day readmission risks and reported them as adjusted hazard ratios (aHR). Kaplan-Meier curves and log-rank tests verified readmission risks.</p><p><strong>Results: </strong>A total of 673059 patients with the principal diagnosis of AP were included. Of these, 5.1% had APFC on initial admission. After propensity score matching, each cohort consisted of 33914 patients. Those with APFC showed a higher incidence of inpatient complications, including septic shock (3.1% <i>vs</i> 1.3%, <i>P</i> < 0.001), portal venous thrombosis (4.4% <i>vs</i> 0.8%, <i>P</i> < 0.001), and mechanical ventilation (1.8% <i>vs</i> 0.9%, <i>P</i> < 0.001). The length of stay (LOS) was longer for APFC patients [4 (3-7) <i>vs</i> 3 (2-5) days, <i>P</i> < 0.001], as were hospital charges ($29451 <i>vs</i> $24418, <i>P</i> < 0.001). For 30-day readmissions, APFC patients had a higher rate (15.7% <i>vs</i> 6.5%, <i>P</i> < 0.001) and a longer median readmission LOS (4 <i>vs</i> 3 days, <i>P</i> < 0.001). The APFC group also had higher readmission charges ($28282 <i>vs</i> $22865, <i>P</i> < 0.001). The presence of APFC increased the risk of readmission twofold (aHR 2.52, 95% confidence interval: 2.40-2.65, <i>P</i> < 0.001). The independent risk factors for 30-day readmission included female gender, Elixhauser Comorbidity Index ≥ 3, chronic pulmonary diseases, chronic renal disease, protein-calorie malnutrition, substance use disorder, depression, portal and splenic venous thrombosis, and certain endoscopic procedures.</p><p><strong>Conclusion: </strong>Developing APFC during index hospitalization for AP is linked to higher readmission rates, more inpatient complications, longer LOS, and increased heal","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"92052"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver surface depressions in the presence of diaphragmatic muscular bands on trans-illumination.","authors":"Shamir O Cawich, Michael T Gardner, Ramanand Shetty, Jean Pierre Louboutin, Zenica Dabichan, Shaneeta Johnson","doi":"10.5493/wjem.v14.i2.92157","DOIUrl":"10.5493/wjem.v14.i2.92157","url":null,"abstract":"<p><p>Traditional descriptions of liver anatomy refer to a smooth, convex surface contacting the diaphragm. Surface depressions are recognized anatomic variants. There are many theories to explain the cause of the depressions. We discuss the theory that these are caused by hypertrophic muscular bands in the diaphragm.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 2","pages":"92157"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}